The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...